Article

Florida Biologix Enters Manufacturing Agreement with America Stem Cell

Florida Biologix (Alachua, FL) has signed a development and manufacturing contract with America Stem Cell (Helotes, TX) for a Phase 1 cell therapy product, ASC-101. ASC-101 is a human recombinant enzyme technology that increases the efficiency of engraftment in transplantation of cord blood derived stem cells.

Florida Biologix (Alachua, FL) has signed a development and manufacturing contract with America Stem Cell (Helotes, TX) for a Phase 1 cell therapy product, ASC-101. ASC-101 is a human recombinant enzyme technology that increases the efficiency of engraftment in transplantation of cord blood derived stem cells.

ASC-101 has been proven to accelerate hematopoietic and immune system recovery, reducing the treatment-related mortality rate associated with infections during the patient’s immune-compromised period. ASC-101 also may enable adult cancer patients requiring bone marrow transplants to be treated quickly with cord-blood derived stem cells from a single cord blood unit, avoiding the long and often-futile wait for matching bone marrow or peripheral-blood derived stem cells.

Florida Biologix will conduct process and assay development, an engineering run, final cGMP manufacturing, and purification of the enzyme. The company also will conduct a formulation and fill-and-finish of the substrate that will be used, along with the enzyme, for the Phase 1 clinical trial targeted to start at University of Texas MD Anderson Cancer Center in early 2010.

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Related Videos
How the 15% US-EU Tariff Cap Affects Bio/pharma
Dave Miller, PhD, Chief Scientific Officer, AustinPx
Dave Miller, PhD, Chief Scientific Officer, AustinPx
© 2025 MJH Life Sciences

All rights reserved.